This Week Last Year in Medtech: June 4-10

See what BD, Medtronic, and Abbott were up to this time last year.

Katie Hobbins, Managing Editor

June 8, 2023

2 Min Read
Calendar pages
Archive Holdings Inc. / The Image Bank via Getty Images

With Diabetes In Its Rear-View Mirror, BD Set to Leap into Pharmacy Automation

The Franklin Lakes, NJ-based company said it would acquire Parata Systems for $1.5 billion.

Never Scoop Poop for Microbiome Testing Again

New Microbiome Wipes eliminate the awkward poop-and-scoop step of at-home microbiome testing.

Real-World Data Supports Medtronic's Next-Gen Insulin Pump

Data presented at the American Diabetes Association meeting shows that using the Medtronic MiniMed 780G insulin pump improves glycemic outcomes with less effort from patients.

The Year of the Medtech CEO Turnover

Better Therapeutics, a digital prescription therapeutics company, is the latest to announce a CEO transition. There have been a string of high-level CEO changes this year.

Top Diabetes Players Hope for Broader CGM Reimbursement

Executives at both Abbott and Dexcom are hopeful that Medicare will extend coverage for continuous glucose monitoring systems to type 2 basal-only patients in 2023, an analyst reports.

Proscia’s Cocentriq Scores IVDR

This new regulatory framework replaces the IVD Directive, under which Concentriq Dx also received a CE mark.

A New Molecular Test for Monkeypox

BD & Certest BioTec are developing a molecular test for the detection of the monkeypox virus.

Here's Why IME South Will Be a Game Changer

IME will take place June 14-16 at the Charlotte Convention Center.

AI-Powered Cancer Detection and Monitoring Coming to India

A partnership between C2i Genomics and Karkinos Healthcare will enable whole-genome-sequencing minimal residual disease (MRD) cancer testing in India.

Why Healthcare Leaders Worldwide Are Rebooting Priorities

Healthcare leaders are re-evaluating priorities to address key challenges coming out of the pandemic, according to a new report published by Philips.

HVAD Problems Still Linger for Medtronic

FDA has issued a Class I Recall for the HVAD pump implant kit because of a pump weld defect.

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like